UK markets closed

Akoya Biosciences, Inc. (AKYA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.3600-0.0500 (-2.07%)
At close: 04:00PM EDT
2.2900 -0.07 (-2.97%)
After hours: 05:58PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 116.55M
Enterprise value 140.16M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.19
Price/book (mrq)3.56
Enterprise value/revenue 1.50
Enterprise value/EBITDA -6.83

Trading information

Stock price history

Beta (5Y monthly) 1.34
52-week change 3-65.40%
S&P500 52-week change 320.87%
52-week high 37.2950
52-week low 31.8800
50-day moving average 32.4581
200-day moving average 34.0341

Share statistics

Avg vol (3-month) 3350.44k
Avg vol (10-day) 3194k
Shares outstanding 549.39M
Implied shares outstanding 649.39M
Float 817.64M
% held by insiders 111.37%
% held by institutions 172.28%
Shares short (28 Jun 2024) 42.6M
Short ratio (28 Jun 2024) 47.26
Short % of float (28 Jun 2024) 48.70%
Short % of shares outstanding (28 Jun 2024) 45.26%
Shares short (prior month 31 May 2024) 42.04M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024


Profit margin -72.68%
Operating margin (ttm)-92.85%

Management effectiveness

Return on assets (ttm)-22.59%
Return on equity (ttm)-181.72%

Income statement

Revenue (ttm)93.57M
Revenue per share (ttm)1.99
Quarterly revenue growth (yoy)-14.30%
Gross profit (ttm)N/A
EBITDA -47.04M
Net income avi to common (ttm)-68M
Diluted EPS (ttm)-1.4200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)61.58M
Total cash per share (mrq)1.25
Total debt (mrq)85.19M
Total debt/equity (mrq)260.33%
Current ratio (mrq)3.07
Book value per share (mrq)0.66

Cash flow statement

Operating cash flow (ttm)-51.97M
Levered free cash flow (ttm)-33.59M